Activity Info

This program addresses the lack of awareness of MA-PAH (methamphetamine associated pulmonary arterial hypertension), including its epidemiology, clinical characteristics, and known pathophysiology; improving early detection, screening, and diagnosis of MA-PAH; and integrating approaches to the treatment of MA-PAH that seek to address both the PAH and underlying substance use disorder.